OTCMKTS:EMMA Emmaus Life Sciences (EMMA) Stock Price, News & Analysis $0.05 -0.01 (-20.14%) As of 10/26/2026 11:51 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartEarningsNews and TrendsSEC Filings About Emmaus Life Sciences Stock (OTCMKTS:EMMA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Emmaus Life Sciences alerts:Sign Up Key Stats Today's Range$0.05▼$0.0550-Day Range$0.01▼$0.0852-Week Range$0.01▼$0.09Volume15,500 shsAverage Volume9,792 shsMarket Capitalization$3.23 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Emmaus Life Sciences, Inc. is a biopharmaceutical company focused primarily on developing and commercializing treatments for rare and serious diseases. The company’s best-known product is Endari (L-glutamine), an oral powder approved by the U.S. Food and Drug Administration to reduce the acute complications of sickle cell disease in adults and children aged five and older. Historically, Emmaus has concentrated on therapies for sickle cell disease and other conditions with significant unmet medical needs. Its activities have included product development, regulatory submissions, manufacturing, and commercialization, with Endari serving as its principal marketed therapy. The company has also investigated additional applications for L-glutamine and other potential treatments. Emmaus Life Sciences has been based in California and has served the U.S. market through its pharmaceutical operations. Publicly available information about the company’s current operations and leadership is limited, so details regarding its present management structure and geographic reach may have changed.AI Generated. May Contain Errors. Read More Emmaus Life Sciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks31st Percentile Overall ScoreEMMA MarketRank™: 1.525742445855 of 5 starsEmmaus Life Sciences scored higher than 31% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Emmaus Life Sciences. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Emmaus Life Sciences is -0.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Emmaus Life Sciences is -0.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.01% of the float of Emmaus Life Sciences has been sold short.Short Interest Ratio / Days to CoverEmmaus Life Sciences has a short interest ratio ("days to cover") of 0.15, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Emmaus Life Sciences has recently decreased by 78.42%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldEmmaus Life Sciences does not currently pay a dividend.Dividend GrowthEmmaus Life Sciences does not have a long track record of dividend growth. News and Social Media3.8 / 5News SentimentN/A News SentimentEmmaus Life Sciences has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 1 news article for Emmaus Life Sciences this week, compared to 0 articles on an average week.Search Interest1 people have searched for EMMA on MarketBeat in the last 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Emmaus Life Sciences insiders have not sold or bought any company stock.Percentage Held by Insiders35.00% of the stock of Emmaus Life Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions7.42% of the stock of Emmaus Life Sciences is held by institutions.Read more about Emmaus Life Sciences' insider trading history. Receive EMMA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Emmaus Life Sciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. EMMA Stock News HeadlinesEmmaus Life Sciences Announces Agreement for Evaluation of L-glutamine for Pancreatic CancerAugust 31, 2026 | businesswire.comEmmaus Life Sciences Reports Quarterly Financial ResultsMay 15, 2026 | businesswire.comDo this before December or regret itPorter Stansberry believes President Trump will use the December G20 Summit in Miami to unveil a radical monetary reset tied to executive order 14241 - one he says could draw a sharp dividing line between prepared investors and those left behind. The last time America reset its money - under Nixon in the 1970s - it produced an average of 1,300 new millionaires per day for over 50 years. Stansberry's new documentary names a core group of assets he believes are positioned to surge as Trump's new dollar rolls out. Watch Porter Stansberry's full briefing and get his three steps to prepare before December.October 27 at 1:00 AM | Porter & Company (Ad)Emmaus Life Sciences Reports Annual Financial ResultsMarch 30, 2026 | businesswire.comEmmaus Life Sciences grants NeoImmuneTech Endari distribution rightsDecember 31, 2025 | msn.comEmmaus Life Sciences enters license, distribution agreement with NeoImmuneTechDecember 31, 2025 | msn.comEmmaus, NIT sign Endari distribution agreementDecember 31, 2025 | finance.yahoo.comEmmaus Life Sciences restructures convertible debt via exchangeDecember 22, 2025 | tipranks.comSee More Headlines EMMA Stock Analysis - Frequently Asked Questions How have EMMA shares performed this year? Emmaus Life Sciences' stock was trading at $0.0130 at the start of the year. Since then, EMMA stock has increased by 253.8% and is now trading at $0.0460. How were Emmaus Life Sciences' earnings last quarter? Emmaus Life Sciences, Inc. (OTCMKTS:EMMA) released its quarterly earnings data on Friday, August, 14th. The company reported $0.02 earnings per share for the quarter. The business had revenue of $6.32 million for the quarter. How do I buy shares of Emmaus Life Sciences? Shares of EMMA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Emmaus Life Sciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Emmaus Life Sciences investors own include Tesla (TSLA), Bloom Energy (BE), CVS Health (CVS), Anavex Life Sciences (AVXL), FuelCell Energy (FCEL), Cassava Sciences (FLNA) and Jazz Pharmaceuticals (JAZZ). Company Calendar Last Earnings8/14/2026Today10/27/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolOTCMKTS:EMMA CIK822370 Webwww.emmausmedical.com Phone(310) 214-0065Fax866-294-2611Employees33Year Founded2000Profitability EPS (Trailing Twelve Months)($0.09) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$7.49 million Net Margins-38.78% Pretax Margin-34.93% Return on EquityN/A Return on Assets-31.18% Debt Debt-to-Equity RatioN/A Current Ratio0.09 Quick Ratio0.07 Sales & Book Value Annual Sales$12.45 million Price / Sales0.26 Cash FlowN/A Price / Cash FlowN/A Book Value($0.91) per share Price / Book-0.05Miscellaneous Outstanding Shares70,190,000Free Float45,622,000Market Cap$3.23 million OptionableNot Optionable Beta9.73 Social Links 7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free Report This page (OTCMKTS:EMMA) was last updated on 10/26/2026 by MarketBeat.com Staff. From Our PartnersFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | Sponsored80 Days Until America's Rare Earth Supply Chain ShiftChina controls more than 90% of global rare earth alloy production, leverage it is using to restrict exports t...The Tomorrow Investor | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredMy next big call (under $1)17,556% on KDA. 3,900% on PRE. 2,650% on OCEAN. Every single one of these was recommended to our community bef...Crypto 101 Media | SponsoredHe turned $12K into $1.65M without touching Apple or TeslaTim Sykes turned $12,415 in gift money into more than $1.65 million before graduating college, without trading...Tim Sykes | SponsoredLast call for your free 0DTE reportThe 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, p...Profits Run | SponsoredWhy Gerardo Del Real says wait before buying uranium stocksGerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...Digest Publishing | SponsoredElon Musk’s Hushed FCC Filing. Dec 8th.Elon Musk quietly filed a document with the federal government tied to artificial intelligence, one of the lar...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Emmaus Life Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Emmaus Life Sciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
